Skip to main content
. 2020 Oct 9;12(10):950. doi: 10.3390/pharmaceutics12100950

Figure 3.

Figure 3

Biocompatibility investigation in A549 or A549/T cells after treatment for 24 h at concentrations that varied from 1 to 1000 µg/mL; n = 3.

HHS Vulnerability Disclosure